Basic statistics about advanced prostate cancer.
A recent phase II clinical trial described at the 2019 ASCO GU meeting using a combination of two immunotherapy drugs in metastatic prostate cancer has shown some positive activity.
At the recent ASCO GU conference, we learned the results from the ARAMUS phase III trial which evaluated Darolutamide, an androgen receptor (AR) antagonist (a drug that prevents androgens from affecting prostate and prostate cancer cells). The trial studied the efficacy and safety of darolutamide in men with nmCRPC men.
African American Men experience a survival advantage over Caucasian Men when they take either Zytiga or Xtandi.
Co-pay assistance is now available for advanced Prostate Cancer drugs.
A preplanned early analysis of the Phase III TITAN trial shows that Erleada (apalutamide) has met the both of the trial’s primary endpoints in the treatment of men with metastatic castration-sensitive prostate cancer (CSPC).
The Food and Drug Administration (FDA) has approved a new Phase 1 clinical trial to evaluate ARV-110 for men with metastatic castration-resistant prostate cancer (mCRPC).
Health Canada has recently approved an expanded use for enzalutamide (Xtandi) so that it can now be prescribed to treat men with non-metastatic castration-resistant prostate cancer (nmCRPC).
Sub-group analysis of the clinical trial ERA 223 signal that the concerns about the use in combination of Zytiga and Xofigo might not cause a significant increase in the risk for developing bone fractures if a man is also simultaneously on a bone targeted therapy.
Palliative care improves a person’d quality of life and it also can extend a person’s survival.
In a small, 25 man, but significant clinical trial of men with metastatic castrate-resistant prostate cancer (mCRPC) who also qualified for Radium-223 (Xofigo) it was shown that the level of pain a man has during the treatment could be used as a prognostic tool of his survival.
Get help with your drug co-pays
In an analysis of the NRG Oncology clinical trial NRG-RTOG 9202 it was shown that the interval of time to biochemical reoccurrence (PSA only or BCR), or the time it takes for previously treated prostate cancer to return as indicated by a prostate-specific antigen (PSA) rise, could be used as a surrogate endpoint for survival for men with locally advanced prostate cancer.
It was announced today that the Phase 3 ARCHES trial which evaluated XTANDI (enzalutamide) along with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) met its primary endpoint, significantly improving radiographic progression-free survival (rPFS) versus ADT alone.
Prostate cancer treatments, particularly hormone therapy (ADT) can have a significant effect on speeding up the process of thinning and weakening the bones. There are some available treatments (Zoledronic acid aka Zoladex and denosumab aka Xgeva) which are designed to slow down or reverse this process; however, they are known to have many adverse side effects themselves. These side effects can include severe fractures of the femur which could limit survival and cataracts. For this reason, these treatments are usually used later, when men become castrate resistant and metastatic.
A recent finding shows that men with a Gleason score of 9–10 prostate cancer may derive a smaller survival benefit from androgen deprivation therapy (ADT) compared with those with Gleason score of 8.
According to Anthony V. D’Amico, MD, Ph.D., who is chief of the Division of Genitourinary Radiation Oncology and an institute physician at Dana-Farber Cancer Institute at Brigham and Women’s Hospital in Boston, “It makes logical sense that in these very aggressive prostate cancers, you need a multi-modality approach.”
At the ESMO 2018 Conference that was recently concluded, there was a report of the clinical experience of 100 men with metastatic castrate resistant prostate cancer (mCRPC) who were consecutively treated with Lu-177 PSMA-I&T Radioligand Therapy.
The understanding that the earlier Provenge is used in castrate resistant men with prostate cancer has led many men to ask why not use Provenge even earlier when they are still castrate sensitive? This question is an excellent one which follows the logical next step; however, the answer is surprising!
According to the results of the STAMPEDE trial.1 adding radiotherapy (radiation) to the current standard-of-care androgen deprivation therapy (ADT of hormone therapy) did not improve the overall survival in all men who are newly diagnosed metastatic prostate cancer.